Marizev (omarigliptin) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 12 Diseases   1 Trial   1 Trial   155 News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Marizev (omarigliptin) / Merck (MSD)
NCT06449235: Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

Not yet recruiting
4
938
RoW
Omarigliptin, Sulphonylureas, Metformin, Other DPP4-i, Thiazolidinediones, Alpha-Glucosidase Inhibitor, Glucagon-Like Peptide-1, Receptor Agonists (GLP1RA), SGLT2 inhibitors
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders, Pi Research and Development Center, Acme Laboratories Ltd.
Type2diabetes
04/25
06/25

Download Options